Table 1 Clinical and pathological characteristics
Clinicopathological variable | Number (%) * | |
|---|---|---|
Age (years) | 65 (59–72) | |
Gender | Male | 36 (59.0%) |
Female | 25 (41.0%) | |
Clinical T stage | cT2 | 27 (44.3%) |
cT3 | 20 (32.8%) | |
cT4 | 14 (23.0%) | |
Histological subtype | NOS | 34 (55.7%) |
NOS with glandular | 2 (3.3%) | |
NOS with lymphoepithelioma-like | 1 (1.6%) | |
NOS with microcystic | 1 (1.6%) | |
NOS with micropapillary | 2 (3.3%) | |
NOS with nested | 1 (1.6%) | |
NOS with plasmacytoid | 3 (4.9%) | |
NOS with sarcomatoid | 3 (4.9%) | |
NOS with small cell | 6 (9.8%) | |
NOS with squamous | 8 (13.1%) | |
Type of neoadjuvant chemotherapy | Gemcitabine + cisplatin | 40 (65.6%) |
Gemcitabine + cisplatin + paclitaxel | 6 (9.8%) | |
Gemcitabine + carboplatin | 3 (4.9%) | |
Gemcitabine + carboplatin + paclitaxel | 2 (3.3%) | |
Methotrexate + vinblastine + doxorubicin + cisplatin †| 4 (6.6%) | |
Etoposide + Cisplatin ‡ | 4 (6.6%) | |
Etoposide + Carboplatin | 2 (3.3%) | |
Type of surgery | Partial cystectomy | 4 (6.6%) |
Radical cystectomy | 57 (93.4%) | |
Pathological staging on cystectomy | ypT0 | 19 (31.1%) |
ypTa | 2 (3.3%) | |
ypTis | 6 (9.8%) | |
ypT1 | 7 (11.5%) | |
ypT2 | 7 (11.5%) | |
ypT3 | 15 (24.6%) | |
ypT4 | 5 (8.2%) | |
Time interval (days) | Neoadjuvant chemotherapy to MRI | 14 (7–23) |
MRI to cystectomy | 33 (24–42) | |
Cystectomy to follow-up | 461 (162–1048) | |